Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Tandem Diabetes Care Q3 2026 Results: Net Loss of $7.08M, Loss Narrows

Tandem Diabetes Care reported sales of $283.7 million for the third quarter of 2026, a 14% increase year-over-year, while significantly narrowing its quarterly net loss to $7.1 million from $21.2 million in 2025. The company strengthened its balance sheet by issuing convertible senior notes due 2032, contributing to a total asset base of $1.16 billion as of September 30, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue283.7249.3
Gross profit160.4134.3
Profit before tax-7.7-25.1
Net income-7.1-21.2
EPS (diluted, $ a share)$-0.10$-0.31

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+13.8%
Gross margin56.5%
Operating margin-0.8%
Source

10-Q filed with the SEC, NASDAQ: TNDM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Tandem Diabetes Care Inc: key numbers

Share price
$18.48Close, Nov 16
Market cap
$1.29B
Shares outstanding
69.79MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Tandem Diabetes Care Inc

All →
8:36 AM ET 8-K
Regulatory Approval

Tandem Diabetes Care Regulatory Approval

Tandem Diabetes Care received FDA 510(k) clearance for Tandem Mobi, the world's first and only tubeless automated insulin delivery system with up to 7 days of wear. The clearance allows the pump to offer both tubed and tubeless infusion options, with a full commercial launch planned for the first half of 2027.

4:13 PM ET 8-K
Financial Results

Tandem Diabetes Care Financial Results

Tandem Diabetes Care reported Q3 2026 worldwide sales of $283.7 million, a 14% increase year-over-year, driven by strong international growth and expanded pump shipments. The company significantly narrowed its net loss to $7.1 million and reaffirmed its full-year 2026 sales guidance of $1.065 billion to $1.085 billion.

Term
Q3 2026

“Tandem’s third-quarter performance demonstrates that our strategy is delivering results. We are expanding access to Tandem’s life-changing technology, strengthening our business model, advancing our pipeline and driving greater operating efficiency, creating a stronger foundation for sustainable, profitable growth.”

John Sheridan, president and chief executive officer
4:07 PM ET Form 4
Insider Selling

Tandem Diabetes Care Insider Christopher J. Twomey Sells $32.6K of Stock

Christopher J. Twomey sold 1,700 shares of Tandem Diabetes Care Inc at $19.15 a share, worth $32.6K in total on Oct 27, 2026. Shares held after the trade: 24,434 (-6.5%).

Value
$32.6K
Shares
1,700
Price
$19.15
Holding change
-6.5%
Trade date
Oct 27, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.